Trending menu:
Latest Content
Takeda reports further results from VARSITY ulcerative colitis study
Takeda Pharmaceutical has reported further results from the VARSITY study, which indicated the gut-selective biologic vedolizumab (Entyvio) being superior to the anti-tumor necrosis factor-alpha (anti-TNFα) biologic adalimumab (Humira) for ulcerative colitis.
Could PF-06480605 Phase IIb trial registration pave the way for Pfizer’s dominance in UC space?
Pfizer's PF-06480605 is an antibody that blocks tumour necrosis factor.
JAK inhibitor ulcerative colitis trial delays triggered by the paucity of eligible patients
According to experts, biologic-naïve patients usually enrolled along with pretreated patients, are harder to recruit.
Janssen starts dosing in REEF-1 Phase IIb trial to treat hepatitis B
Arrowhead Pharmaceuticals has announced that Janssen has started dosing in a REEF-1 Phase IIb study of different combination regimens, including JNJ-3989, and/or JNJ-6379, and a nucleos(t)ide analogue (NA) to treat patients with chronic hepatitis B virus (HBV) infection.
Acurx finishes trial of ACX-362E in clostridioides difficile infection
Clinical stage biopharmaceutical company Acurx Pharmaceuticals has completed the Phase I trial of ACX-362E for the treatment of clostridioides difficile infection (CDI).
InDex reports positive results from Phase IIb trial of cobitolimod
InDex Pharmaceuticals has reported positive results from the Phase IIb CONDUCT trial evaluating cobitolimod for the treatment of moderate to severe ulcerative colitis.
Abivax starts enrolment in Phase IIb ulcerative colitis study
Abivax has recruited the first patient for a Phase IIb clinical trial assessing oral, once-daily ABX464 to treat moderate to severe active ulcerative colitis (UC).
Mallinckrodt’s terlipressin shows positive profile in CONFIRM study
Mallinckrodt has reported positive data from the Phase III CONFIRM trial of terlipressin conducted in hepatorenal syndrome type 1 (HRS-1) patients.
Alkermes-Biogen’s MS drug shows improved GI tolerability
Alkermes and Biogen have reported that diroximel fumarate demonstrated a statistically superior gastrointestinal (GI) tolerability profile compared to Tecfidera (dimethyl fumarate) in a Phase III EVOLVE-MS-2 study for relapsing-remitting multiple sclerosis (RRMS).
Takeda’s study of subcutaneous vedolizumab meets primary goal
Takeda Pharmaceutical has reported that the VISIBLE 2 clinical trial of a subcutaneous (SC) formulation of vedolizumab met its primary endpoint in adults with moderately to severely active Crohn's disease (CD).
Related Treatments
Close
Close
Close
Go Top
